Vaxess is a high-potential, venture-backed biotech (Series B, ~$90M funding) developing MIMIX sustained-release patches. While the project has exceptional technical innovation and real-world utility, the submission itself contained facetious claims (e.g., 'most people have used my product') which heavily penalized the Response Quality and Traction evidence scores. The score reflects the company's verified external status as a significant player in drug delivery, adjusted for the lack of credible user data provided in the input.
Ready to Compete for $150k+ in Prizes?
Move this data into a HackerNoon blog draft to become eligible for your share of $150k+ in cash and software prizes
Score Breakdown
Project Details
Algorithm Insights
Recommendations to Increase Usefulness Score
Document User Growth
Provide specific metrics on user acquisition and retention rates
Showcase Revenue Model
Detail sustainable monetization strategy and current revenue streams
Expand Evidence Base
Include testimonials, case studies, and third-party validation
Technical Roadmap
Share development milestones and feature completion timeline